Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $3.9 million.

  • Karyopharm Therapeutics' Share-based Compensation rose 100.93% to $3.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.0 million, marking a year-over-year decrease of 2374.91%. This contributed to the annual value of $14.0 million for FY2025, which is 2374.91% down from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Share-based Compensation of $3.9 million as of Q4 2025, which was up 100.93% from $2.8 million recorded in Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Share-based Compensation peaked at $15.1 million during Q2 2022, and registered a low of $2.8 million during Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' median Share-based Compensation value was $5.4 million (recorded in 2023), while the average stood at $6.0 million.
  • Per our database at Business Quant, Karyopharm Therapeutics' Share-based Compensation surged by 8553.17% in 2022 and then tumbled by 5984.89% in 2023.
  • Over the past 5 years, Karyopharm Therapeutics' Share-based Compensation (Quarter) stood at $6.9 million in 2021, then decreased by 10.13% to $6.2 million in 2022, then dropped by 16.05% to $5.2 million in 2023, then decreased by 25.43% to $3.9 million in 2024, then increased by 1.01% to $3.9 million in 2025.
  • Its Share-based Compensation was $3.9 million in Q4 2025, compared to $2.8 million in Q3 2025 and $3.8 million in Q2 2025.